Related Experiment Video
Updated: Jun 27, 2026
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
8.2K
Clinical Utility of Patient-Derived Cell-Based In Vitro Drug Sensitivity Testing for Optimizing Adjuvant Therapy in
Young-Rok Kim1,2, Kieun Bae1,3, Ja-Young Lee1,3
1KU Animal Cancer Center, Konkuk University Veterinary Medical Teaching Hospital, Seoul 05029, Republic of Korea.
Animals : an Open Access Journal From MDPI
|April 26, 2025
Summary
In vitro drug sensitivity testing improved cancer treatment outcomes in dogs with solid tumors. This personalized approach led to significantly longer tumor progression times compared to standard methods.
Area of Science:
- Veterinary Oncology
- Cancer Therapeutics
- Preclinical Models
Background:
- Inter-individual variability in drug response is a challenge in veterinary oncology.
- Preclinical models are crucial for predicting drug efficacy and tailoring cancer therapy.
- Patient-derived cell cultures offer a promising avenue for personalized treatment strategies.
Purpose of the Study:
- To assess the clinical utility of in vitro drug sensitivity testing (DST) in selecting adjuvant therapies for dogs with solid tumors.
- To compare treatment outcomes between dogs receiving DST-guided therapy and those receiving empirically chosen treatments.
- To identify specific canine patient subgroups that may benefit most from DST-guided adjuvant therapy.
Main Methods:
- Retrospective analysis of 126 dogs with suspected tumors, focusing on 33 with solid tumors divided into guided and empirical groups.
- Adjuvant anticancer drug selection was based on DST results in the guided group and histopathology in the empirical group.
- Time to tumor progression (TTP) was the primary endpoint for comparing treatment efficacy between the two groups.
Main Results:
- The DST-guided group demonstrated a significantly longer median Time to Tumor Progression (TTP) of 949 days compared to 109 days in the empirical group.
- Extended TTP was observed in the guided group for dogs with incomplete surgical margins, low mitotic counts, no initial metastatic disease, and those treated with tyrosine kinase inhibitors.
- The guided group showed superior outcomes across multiple prognostic indicators, highlighting the effectiveness of DST.
Conclusions:
- In vitro drug sensitivity testing is a valuable tool for optimizing adjuvant therapy selection in canine solid tumors.
- Personalized medicine approaches, guided by DST, can significantly improve progression-free survival in dogs with cancer.
- Further research into DST applications could enhance treatment strategies in veterinary oncology.
